Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive the group has recently enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme (GBM) study of its VAL-083 drug. Zarrabian says the recurrent arm of the study addresses patients suffering from GBM who have been pre-treated with the drug temozolomide (TMZ) prior to disease recurrence. The trial is designed to treat up to 83 patients to determine whether treatment with VAL-083 improves overall survival.
Kintara achieves 'major milestone' by enrolling last patient in Phase 2 trial to treat brain cancer
